• Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload
  • Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with Heart Failure

ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that two abstracts demonstrating utilization of its SOZO® device will be presented during poster presentations by A.J. Accardi, M.D. at the upcoming American Heart Congress – CVD, October 5-6, 2018, Los Angeles: Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload and Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with Heart Failure. These abstracts are expected to be published online in advance of the Congress poster sessions.

This follows on from a successful presentation by Dr. Accardi at the recent World Congress on Heart Disease, sponsored by the International Academy of Cardiology. Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload, was published online at https://www.karger.com/Article/Pdf/491714 (page 143).

Dr. Accardi explains, “There has been a push to identify early markers of impending congestion as well as measures of treatment efficacy as means of providing a cost savings and value in the management of Heart Failure (HF) by preventing admissions. In Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload, we evaluated the correlation between BIS readings from a SOZO unit and a pulmonary artery diastolic (PAD) device. Findings from the case referenced in the abstract suggest that BIS correlates well with diastolic pulmonary artery pressures and may provide an additional noninvasive tool to detect extracellular fluid excess and impending congestion before hospitalization. BIS could prove a useful adjunct in the management of HF.”

The second abstract, Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with Heart Failure, demonstrates excellent correlations with BIS measurements and IVC size, right atrial pressure and pulmonary artery systolic pressure measurements. This suggests a possible alternative method to detect fluid overload despite the small sample size. Trending a patient's impedance using the SOZO device at home or the practitioner's office may assist clinicians in providing more accurate, individualized HF care.

Richard Carreon, managing director and CEO, ImpediMed, says, “Available by prescription only, SOZO is the world’s first bioimpedance spectroscopy (BIS) device FDA-cleared to monitor a heart failure patient’s fluid status in a clinical or at-home setting, SOZO is the most detailed and accurate BIS device available, designed to create a customized plan around individual patients.”

He explains that SOZO not only analyzes personal data but will also use population health data to compare individual data with others of similar demographics to better understand each patient’s health needs.

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.

For ImpediMedLaura Carabello, 201-641-1911 x12lcarabello@cpronline.com

Impedimed (ASX:IPD)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Impedimed.
Impedimed (ASX:IPD)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Impedimed.